

# The role of magnetic navigation for catheter ablation of ventricular arrhythmias

Pekka Raatikainen Heart and Lung Center Helsinki University Hospital Helsinki, Finland

#### **Disclosures**

- Consulting fees / honoraria for lecture
  - Abbott, Biosense Webster, Biotronik, BMS/ Pfizer, Stereotaxis
- Research support
  - Abbott, Biosense Webster
  - Finnish Foundation for Cardiovascular Research

#### Heart and Lung Center Helsinki University Hospital



#### **EP at the Heart and Lung Center**


- About 1000 catheter ablations per year
  - In addition ~100 ablations per year in the New Children's Hospital
  - More than 350 AF cases and >100 VES/VT cases
- About 1000 device implantations per year
  - ILR are implanted by nurses
  - Remote monitoring for all new patients

#### **RMN lab in Helsinki**

- Genesis RMN system with Stereotaxis (Omega Medical) xray system was installed last summer first in the world
  - First cases in July 23, 2020
- The system is used every day
  - Idiopathic VES/VT
  - VTs in patients with structural heart disease
  - Arrhythmias in patients with congenital heart disease
  - Atrial fibrillation
  - SVTs using the Odyssey Navicant screen

#### GENESIS RMN ™ System

Odyssey Vision<sup>™</sup> and Cinema<sup>™</sup> System



# Why do we use RMN in ventricular tachyarrhytmia ablation?

- Catheter precicion, reach and stability are better than in manual ablations
  - Retrograde ablations in left atrium in patients with GUCH or vascular abnormalities
- Improved safety
  - Risk of perforation is markedly lower when using soft RMN catheter than stiff manual catheters
- Reduced radiation exposure
- Less complexity in operations
  - No need to wear lead apron or sterile clothing and cloves
  - Ergonomic advantages
  - Easy to change operator during long cases
- Shallow learning curve
  - Remote operation and support via Odyssey Cinema system

Patients feel better!

Operators stay healthier!

### **Management of VT/VF**


#### Identification and treatment of reversible causes

- Ischemia
- Electrolyte disturbances
- Proarrhythmia...
- Medical treatment of the underlying disease
  - Betablockers (bisoprolol, carvedilol, metoprolol)
  - ACEI / ARB
  - MRA
  - Statins
- Antiarrhythmic medication
- Invasive treatment
  - Revascularization
  - ICD/CRT-D
  - Catheter ablation
  - Arrhythmia surgery

#### **RMN** in treatment of various arrhythmias

- RVOT / LVOT / Aortic cusp / other right or left ventricular VES and VT in patients with structurally normal heart
  - Endo- and epicardial ablations
  - CartoSound<sup>™</sup>
- Atrial and ventricular arrhyhtmia in patient with GUCH
- Ventricular arrhythmias in patients with structural heart disease
  - Post MI
  - Cardiac sarcoidosis
  - Dilated cardiomyopathy, ARVC: endo- and epicardial mapping

#### **Idiopathic VES/VT ablation in distal CS**



#### **Patient NN**

- 39 year old female
  - Severe palpitations for several years
  - Echo normal
  - MRI normal
  - Family history negative for VT/VF and sudden cardiac death
- Holter recording
  - 30000-45000 monomorphic ventricular extrasystole
- Medication
  - Betablockers
  - Calcium antagonist
  - Flecainide
- 12/2015 catheter ablation
  - Endocardial mapping of LVOT and aortic cusps


No effect


#### **Control Holter after first ablation**

#### VENTRICULAR ECTOPY


Isolated: 39639		beats LON	GEST at:	bpm
Couplets: 0		beats FAST	TEST at:	bpm
Runs: 0				
Total beats: 0		40% of all beats		
Bigeminal: 36832			лап	
SUPRAVENTRICULAR ECTOPY				
Isolated: 3		beats LONGEST at:		bpm
Couplets: 0		beats FASTEST at:		bpm
Runs: 0				
Total beats: 0				
Longest RR: 1.856	sec at:	05:29:08	24-Lok-	2015
			Acq dura	ation: 24:00


#### **12 lead ECG**
















#### **Follow-up after epicardial ablation**





## Holter recording 3 VES (from another focus)

### **VT** ablation in patients with **SHD**

In patients with several ICD therapies (ATP or shocks)

#### **Post-MI**

- Early ablation selected patients
  - MANTRA-VT trial
- Endocardial first

#### Non-ischemic cardiomyopathy

- Escalation of antiarrhytmic drugs before ablation
- Both endo- and epicardial mapping and ablation
  - ARVC
  - Dilated CMP

**General anesthesia** 

Transseptal access to LV (steerable TS sheath to LV just below the mitral valve)

#### **Mapping and Ablation with RMN**

- Mapping with the ablation catheter remotely
  - Occasionally CT/MRI image integration
  - CartoSound<sup>™</sup>
- Ablation
  - Energy always about 10W higher than in manual ablations
  - Contact information and lesion formation is followed using the Ablation history


# Mapping

- Voltage map
  - Automatic collection of data points using pattern matching during sinus or RV paced rhythm
  - Identication of low voltage areas
    - Cut off <0.5 mV and >1.5 mV
    - Avoiding scar tags

#### Tags for late potentials / fragmented signals


- Ripple map
- Need for diagnostic multipole RMN catheter!
- Low treshold for epicardial mapping in patients with nonischemic CMP


Epicardial ablation in a patient with ARVC




Post-MI VT ablation

#### Voltage map Tags on LP and fragmented signals






#### Ripple map



#### **Current approach in Helsinki**



# All types of ventricular arhythmias can be ablated using RMN

С	Polymorphic VT	
	not ablate	M





# Catheter ablation of VT in a patient with cardiac sarcoidosis

Pekka Raatikainen, Hannu Parikka and EP Team Heart and Lung Center Helsinki University Hospital